TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice

MLA

Minnie, Simone A., et al. “TIGIT Inhibition and Lenalidomide Synergistically Promote Antimyeloma Immune Responses after Stem Cell Transplantation in Mice.” Journal of Clinical Investigation, vol. 133, no. 4, Feb. 2023. EBSCOhost, https://doi.org/10.1172/JCI157907.

APA

Minnie, S. A., Waltner, O. G., Ensbey, K. S., Olver, S. D., Collinge, A. D., Sester, D. P., Schmidt, C. R., Legg, S. R. W., Takahashi, S., Nemychenkov, N. S., Sekiguchi, T., Driessens, G., Zhang, P., Koyama, M., Spencer, A., Holmberg, L. A., Furlan, S. N., Varelias, A., & Hill, G. R. (2023). TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice. Journal of Clinical Investigation, 133(4). https://doi.org/10.1172/JCI157907

Chicago

Minnie, Simone A., Olivia G. Waltner, Kathleen S. Ensbey, Stuart D. Olver, Alika D. Collinge, David P. Sester, Christine R. Schmidt, et al. 2023. “TIGIT Inhibition and Lenalidomide Synergistically Promote Antimyeloma Immune Responses after Stem Cell Transplantation in Mice.” Journal of Clinical Investigation 133 (4). doi:10.1172/JCI157907.